Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Louisiana Pancreatic Enzyme Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentBlue Cross and Blue Shield of LouisianaPolicy 00981

    Pancreatic Enzyme Replacement Therapy

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy 00981 alerts

    Get alerted when Policy 00981 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage eligibility for Pancreaze and Pertzye for pancreatic enzyme replacement therapy in eligible members of Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. Coverage requires applicable plan benefits and satisfaction of the policy's medical necessity and preferred-product trial criteria.

    Policy Summary
    PayerBlue Cross and Blue Shield of Louisiana
    PolicyPancreatic Enzyme Replacement Therapy
    Policy CodePolicy 00981
    Change TypeNo material change
    Effective DateJan 1, 202743d
    Last ReviewJul 21, 2026
    Next Review DateJul 1, 2027
    Key ActionSubmit evidence that the patient has tried and failed both Creon and Zenpep, or that clinical evidence or history supports an exception.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Nonpreferred pancreatic enzyme products identified for coverage consideration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Preferred products required before coverage absent an exception
    Adult and pediatricPatient populations indicated for pancreatic enzyme products for exocrine pancreatic insufficiency
    Not medically necessaryPolicy stance when the patient selection criterion is not met

    Coverage Criteria

    Initial coverage criteria for Pancreaze or Pertzye

    Coverage may be considered when benefits are available under the member’s contract and the patient selection criterion is met.

    Coverage prerequisites

    • Benefit availability: Benefits are available under the member’s contract or certificate.
    • Patient selection criterion

      • Preferred-product trial and failure: The patient has tried and failed both Creon and Zenpep due to intolerance or inadequate response.
      • Clinical exception: Clinical evidence or patient history suggests that both Creon and Zenpep will be ineffective or cause an adverse reaction to the patient.

    Investigational or experimental services are excluded from coverage. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study.

    Use of Pancreaze or Pertzye is considered not medically necessary when the patient selection criterion is not met.

    Provider Actions and Documentation

    Documentation Required

    Submit Coverage-Supporting Evidence

    For Pancreaze or Pertzye, submit clinical documentation supporting coverage consideration, including the diagnosis, requested product and the patient-specific rationale for use.

    • Document the relevant clinical evidence and treatment history.
    • Explain why the requested nonpreferred product is needed.
    Step Therapy

    Creon and Zenpep Are Preferred

    Before requesting coverage for Pancreaze or Pertzye, the patient must have tried and failed both Creon and Zenpep, such as due to intolerance or inadequate response, unless an applicable exception is documented.

    • Required sequence: trial and failure of Creon AND Zenpep.
    • The preferred-product requirement applies to both Pancreaze and Pertzye.

    Therapy Background

    Creon, Pancreaze, Pertzye, and Zenpep are pancreatic enzyme replacement products used to treat exocrine pancreatic insufficiency (EPI) in adult and pediatric patients. They contain pancreatic amylases, lipases, and proteases that aid digestion and are taken with meals and snacks. Dosing is based on required lipase units and individualized according to factors such as body weight, symptoms, dietary fat content, and steatorrhea; these products are not interchangeable.

    Defined Terms

    Medically necessary
    DefinitionHealth care services, treatment, procedures, equipment, drugs, devices, items, or supplies that a provider, exercising prudent clinical judgment, would provide to prevent, evaluate, diagnose, or treat an illness, injury, disease, or its symptoms.
    Clinical standardsThe service, treatment, procedure, equipment, drug, device, item, or supply must be in accordance with nationally accepted standards of medical practice and clinically appropriate in type, frequency, extent, level of care, site, and duration, and considered effective for the patient's illness, injury, or disease.
    ExclusionsIt must not be primarily for the personal comfort or convenience of the patient, physician, or other health care provider, and must not be more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results.
    Exocrine pancreatic insufficiency (EPI)
    DefinitionA condition in which pancreatic enzyme replacement products are used to improve digestion and absorption of food, including fat.

    Initial Therapy Criteria

    Pancreaze or Pertzye initial coverage

    Pancreaze or Pertzye may be eligible for initial coverage when benefits are available and the patient selection criterion is met.

    Initial coverage requirements

    • Benefit availability: Benefits are available under the member’s contract or certificate.
    • Preferred-product failure or exception

      • Step therapy failure: The patient has tried and failed both Creon and Zenpep due to intolerance or inadequate response.
      • Clinical exception to step therapy: Clinical evidence or patient history suggests that both Creon and Zenpep will be ineffective or cause an adverse reaction to the patient.

    Preferred Product Step Therapy

    StepPreferred products to tryFailure standardException
    1Creon and ZenpepTried and failed both products due to intolerance or inadequate responseThe sequence may be bypassed when clinical evidence or patient history suggests both products will be ineffective or cause an adverse reaction
    Policy Summary
    PayerBlue Cross and Blue Shield of Louisiana
    PolicyPancreatic Enzyme Replacement Therapy
    Policy CodePolicy 00981
    Change TypeNo material change
    Effective DateJan 1, 202743d
    Last ReviewJul 21, 2026
    Next Review DateJul 1, 2027
    Key ActionSubmit evidence that the patient has tried and failed both Creon and Zenpep, or that clinical evidence or history supports an exception.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationTherapy BackgroundDefined TermsInitial Therapy CriteriaPreferred Product Step Therapy

    Unsupported block type: documentation

    Prior Authorization

    Verify Benefit Eligibility

    Confirm that benefits for the requested treatment are available under the member’s contract or certificate before submitting the request. Pancreaze and Pertzye may be eligible for coverage only when applicable benefits are available and medical-necessity criteria are met.

    • Verify member contract or certificate benefit eligibility.
    • Coverage consideration also requires satisfaction of applicable medical-necessity criteria.
    Denial Risk

    Failure to Meet Preferred Sequence May Result in Denial

    If the patient-selection criterion is not met—specifically, the required trial and failure of both Creon and Zenpep, absent a supported exception—Pancreaze or Pertzye will be denied as not medically necessary.

    • Failure to meet the preferred-product requirement is an additional Company coverage requirement.
    • The resulting determination is not medically necessary.
    Denial Risk

    No Benefit or Medical Necessity, No Coverage

    Coverage is unavailable when benefits for the requested treatment are not provided under the member’s contract or when applicable medical-necessity criteria are not met. Investigational or experimental services are also excluded from coverage under benefits.

    • No contract benefit: coverage is unavailable.
    • Medical-necessity criteria not met: coverage is unavailable.
    • Investigational or experimental services are excluded from coverage.
    Adult applicabilityExocrine pancreatic insufficiency applies to adult patients.
    Pediatric applicabilityExocrine pancreatic insufficiency applies to pediatric patients.
    Pancreatic enzyme replacement therapy (PERT)
    DefinitionPancreatic enzyme replacement therapy uses products containing pancreatic amylases, lipases, and proteases to aid digestion after food is eaten.
    EnzymesPancreatic enzyme products contain a mixture of amylases, lipases, and proteases.
    AdministrationBecause the enzymes need to reach the small intestine at about the same time as food, pancreatic enzyme products are taken with meals and snacks.